Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells

Currently, a common therapeutic approach in cancer treatment encompasses a drug combination to attain an overall better efficacy. Unfortunately, it leads to a higher incidence of severe side effects, namely cardiotoxicity. This work aimed to assess the cytotoxicity of doxorubicin (DOX, also known as...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira-Oliveira, Maria, Reis-Mendes, Ana, Carvalho, Félix, Remião, Fernando, Bastos, Maria de Lourdes, Costa, Vera Marisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358964/
https://www.ncbi.nlm.nih.gov/pubmed/30634681
http://dx.doi.org/10.3390/biom9010021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358964/
https://www.ncbi.nlm.nih.gov/pubmed/30634681
http://dx.doi.org/10.3390/biom9010021

Ejemplares similares